Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.

Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T.

Breast Cancer Res Treat. 2013 Feb;138(1):109-18. doi: 10.1007/s10549-012-2110-9. Epub 2012 Jun 8.

2.

A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing.

Spitzer D, McDunn JE, Plambeck-Suess S, Goedegebuure PS, Hotchkiss RS, Hawkins WG.

Mol Cancer Ther. 2010 Jul;9(7):2142-51. doi: 10.1158/1535-7163.MCT-10-0225. Epub 2010 Jun 22.

3.

Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.

Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG.

Int J Cancer. 2009 Aug 15;125(4):942-51. doi: 10.1002/ijc.24424.

4.

Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.

Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG.

J Transl Med. 2009 Mar 26;7:24. doi: 10.1186/1479-5876-7-24.

5.

Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.

Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunother. 2009 Jan;32(1):12-21. doi: 10.1097/CJI.0b013e318189f13c.

6.

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.

Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC.

J Immunol. 2009 Feb 1;182(3):1746-55.

7.

Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.

Viehl CT, Frey DM, Phommaly C, Chen T, Fleming TP, Gillanders WE, Eberlein TJ, Goedegebuure PS.

Breast Cancer Res Treat. 2008 May;109(2):305-14. Epub 2007 Jul 26.

PMID:
17653857
8.

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.

Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH, Hawkins WG.

Mol Cancer. 2007 Jul 15;6:48.

9.

TAT-Bim induces extensive apoptosis in cancer cells.

Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG.

Ann Surg Oncol. 2007 May;14(5):1763-71. Epub 2007 Jan 6.

PMID:
17206479
10.

Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.

Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC.

Ann Surg Oncol. 2006 Sep;13(9):1252-8. Epub 2006 Sep 3.

PMID:
16952047
11.

Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients.

Lin Y, Goedegebuure PS, Tan MC, Gross J, Malone JP, Feng S, Larson J, Phommaly C, Trinkaus K, Townsend RR, Linehan DC.

J Proteome Res. 2006 Sep;5(9):2169-76.

PMID:
16944928
12.

Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.

Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC.

J Immunother. 2006 Jul-Aug;29(4):416-24.

PMID:
16799337
13.

CD25+ CD4+ regulatory T-cells in cancer.

Linehan DC, Goedegebuure PS.

Immunol Res. 2005;32(1-3):155-68. Review.

PMID:
16106066
14.

Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.

Viehl CT, Tanaka Y, Chen T, Frey DM, Tran A, Fleming TP, Eberlein TJ, Goedegebuure PS.

Breast Cancer Res Treat. 2005 Jun;91(3):271-8.

PMID:
15952060
15.

A tat fusion protein-based tumor vaccine for breast cancer.

Viehl CT, Becker-Hapak M, Lewis JS, Tanaka Y, Liyanage UK, Linehan DC, Eberlein TJ, Goedegebuure PS.

Ann Surg Oncol. 2005 Jul;12(7):517-25. Epub 2005 May 10.

PMID:
15889213
16.

Mammaglobin-based strategies for treatment of breast cancer.

Goedegebuure PS, Watson MA, Viehl CT, Fleming TP.

Curr Cancer Drug Targets. 2004 Sep;4(6):531-42. Review.

PMID:
15462037
17.

[Significance if ICAM-1 on lysis of human pancreatic carcinoma cells by autologous, cytotoxic T-lymphocytes].

Peiper M, Goedegebuure PS, Eberlein TJ, Broelsch CE.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):59-62. German.

PMID:
14518213
18.

Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.

Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, Goedegebuure PS.

Surgery. 2003 Jan;133(1):74-80.

PMID:
12563241
19.

Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells.

Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS.

J Immunol. 2003 Feb 1;170(3):1291-8.

20.

Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.

Peiper M, Goedegebuure PS, Alldinger I, Knoefel WT, Izbicki JR, Eberlein TJ.

Anticancer Res. 2002 Nov-Dec;22(6A):3357-63.

PMID:
12530087
21.

Human dendritic cells induce tumor-specific apoptosis by soluble factors.

Joo HG, Fleming TP, Tanaka Y, Dunn TJ, Linehan DC, Goedegebuure PS, Eberlein TJ.

Int J Cancer. 2002 Nov 1;102(1):20-8.

22.

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunol. 2002 Sep 1;169(5):2756-61.

23.

Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.

Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS, Eberlein TJ.

Cancer. 2002 May 15;94(10):2552-60.

24.

Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.

Tanaka Y, Amos KD, Joo HG, Eberlein TJ, Goedegebuure PS.

Int J Cancer. 2001 Nov;94(4):540-4.

25.

Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.

Lockhart DC, Chan AK, Mak S, Joo HG, Daust HA, Carritte A, Douville CC, Goedegebuure PS, Eberlein TJ.

Surgery. 2001 Jun;129(6):749-56.

PMID:
11391375
26.

Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes.

Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ.

J Leukoc Biol. 2001 Apr;69(4):555-64.

PMID:
11310841
27.

B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T-cell receptor.

Chan AK, Goedegebuure PS, von Bernstorff W, Carritte AL, Chung M, Stewart RA, Montgomery L, Spanjaard RA, McKenzie AB, Eberlein TJ.

Surgery. 2000 Mar;127(3):342-50.

PMID:
10715992
28.

Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.

Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ.

Anticancer Res. 1999 Jul-Aug;19(4A):2471-5.

PMID:
10470176
29.

Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation.

Chan AK, Lockhart DC, von Bernstorff W, Spanjaard RA, Joo HG, Eberlein TJ, Goedegebuure PS.

Int J Cancer. 1999 Aug 27;82(5):721-6.

30.

Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.

Sadanaga N, Nagoshi M, Lederer JA, Joo HG, Eberlein TJ, Goedegebuure PS.

J Immunother. 1999 Jul;22(4):315-23.

PMID:
10404433
31.
32.

Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.

von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ.

Surgery. 1999 Jan;125(1):73-84.

PMID:
9889801
33.

T cells mediate treatment of six-day-old cytokine-gene-transfected mouse mammary tumor.

Matory YL, Dorfman DM, Chen M, Wu L, Spanjaard RA, Goedegebuure PS, Eberlein TJ.

Pathobiology. 1999;67(1):3-11.

PMID:
9873222
35.

Clone 10d/BM28 (CDCL1), an early S-phase protein, is an important growth regulator of melanoma.

Spanjaard RA, Lee PJ, Sarkar S, Goedegebuure PS, Eberlein TJ.

Cancer Res. 1997 Nov 15;57(22):5122-8.

36.

Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells.

Peiper M, Goedegebuure PS, Eberlein TJ.

Surgery. 1997 Aug;122(2):235-41; discussion 241-2.

PMID:
9288128
37.

The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.

Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ.

Eur J Immunol. 1997 May;27(5):1115-23.

PMID:
9174600
38.

Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.

Goedegebuure PS, Douville CC, Doherty JM, Linehan DC, Lee KY, Ganguly EK, Eberlein TJ.

Cell Immunol. 1997 Feb 1;175(2):150-6.

PMID:
9023420
39.

Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors.

Goedegebuure PS, Eberlein TJ.

Oncologist. 1997;2(5):300-310.

40.

[Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].

Peiper M, Goedegebuure PS, Eberlein TJ, Zornig C.

Zentralbl Chir. 1997;122(3):141-8. Review. German.

PMID:
9206906
41.

Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro.

Burger UL, Chang MP, Nagoshi M, Goedegebuure PS, Eberlein TJ.

Ann Surg Oncol. 1996 Nov;3(6):580-7.

PMID:
8915492
42.

Vaccine therapy for cancer.

Linehan DC, Goedegebuure PS, Eberlein TJ.

Ann Surg Oncol. 1996 Mar;3(2):219-28. Review.

PMID:
8646525
43.

Anti-tumor effects and tumor immunogenicity following IL2 or IL4 cytokine gene transfection of three mouse mammary tumors.

Matory YL, Chen M, Goedegebuure PS, Eberlein TJ.

Ann Surg Oncol. 1995 Nov;2(6):502-11.

PMID:
8591080
44.

Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ.

J Immunol. 1995 Nov 1;155(9):4486-91.

PMID:
7594611
45.

Shared T cell epitopes in epithelial tumors.

Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ.

Cell Immunol. 1995 Sep;164(2):279-86.

PMID:
7656335
46.

Antitumor activity of three mouse mammary cancer cell lines after interferon-gamma gene transfection.

Matory YL, Chen M, Dorfman DM, Williams A, Goedegebuure PS, Eberlein TJ.

Surgery. 1995 Aug;118(2):251-5; discussion 255-6.

PMID:
7638741
47.

Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.

Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ.

J Clin Oncol. 1995 Aug;13(8):1939-49.

PMID:
7636534
48.

Immunoregulatory effects of CD4+ T helper subsets in human melanoma.

Lee KY, Goedegebuure PS, Linehan DC, Eberlein TJ.

Surgery. 1995 Apr;117(4):365-72.

PMID:
7716716
49.

Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.

Burger UL, Chang MP, Goedegebuure PS, Eberlein TJ, Adams-Hodgins S.

Surgery. 1995 Mar;117(3):325-33. Erratum in: Surgery 1996 Apr;119(4):482.

PMID:
7878540
50.

In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.

Linehan DC, Peoples GE, Hess DT, Summerhayes IC, Parikh AS, Goedegebuure PS, Eberlein TJ.

Surg Oncol. 1995 Feb;4(1):41-9.

PMID:
7780612

Supplemental Content

Loading ...
Support Center